|
Quest for data increases debate for anti-VEGF therapy approach
|
The threshold for treatment with an anti-VEGF agent for diabetic retinopathy without diabetic macular edema is controversial. Two Phase III studies are now investigating aflibercept for moderately severe to severe nonproliferative diabetic retinopathy. |
|
Read more
|
|
|
|
Light-adjustable IOL technology creates novel treatment window
|
 The ability to fine-tune and customize patients’ refractive outcome after cataract surgery could shift the need for physicians to do counseling and decision-making preoperatively more to postoperatively. |
|
Learn More
|
